

REMARKS

Claim 35 is being amended to recite the complete Accession Number of the referenced hybridoma cell line and Claims 88 and 108 are being amended to correct informalities. With regard to recitation of Accession Number PTA-990 in Claim 35, the specification as filed described the 7F3 hybridoma cell line and 7F3 monoclonal antibody at page 4, lines 13-14 and at page 32, line 23 *et seq.* The specification was amended to include the Accession Number in the Preliminary Amendment filed August 27, 2001. No new matter is added by these amendments.

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (978) 341-0036.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Helen E. Wendler

Helen E. Wendler

Registration No. 37,964

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: Nov. 15, 2001

MARKED UP VERSION OF AMENDMENTSClaim Amendments Under 37 C.F.R. § 1.121(c)(1)(ii)

35. (Twice Amended) The isolated cell of Claim 34 wherein said antibody or antigen-binding fragment inhibits a cellular response to binding of ligand to said Bonzo in an *in vitro* assay with an IC_{50} of less than about 7 $\mu\text{g/mL}$.
88. (Twice Amended) The test kit of Claim 84 wherein said antibody or antigen-binding fragment is selected from the group consisting of
- a) mAb 4A11, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-991;
 - b) mAb 7A2, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-992;
 - c) mAb 7F3, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-990;
 - d) an antibody which can compete with mAb 4A11, mAb 7A2 or mAb 7F3 for binding to mammalian Bonzo; and
 - e) an antigen-binding fragment of [(a), (b), (c) or (d)] a), b), c) or d).
108. (Amended) The antibody or antigen-binding fragment of Claim 107 wherein said antibody or antigen-binding fragment has the epitopic specificity of mAb 7F3, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-990.